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Introduction: Recent studies in CF patients demonstrate that the upper airways
are colonized with bacteria of the same genotypes as found in the lower airways,
underlining the necessity of a concomitant treatment of upper and lower airways.
The VibrENT (PARI Pharma, Germany) is a novel device using pulsating airﬂow
and enabling nasal drug delivery to the sites of infection: the osteomeatal complex
and the paranasal sinuses.
Methods: Sinus ventilation, nasal and paranasal aerosol deposition as well as
nasal clearance of aerosols delivered by pulsating airﬂow in comparison to nasal
pump sprays was studied in 16 healthy volunteers using gamma camera imaging
with 81mKr-gas and aerosolized 99mTc-DTPA. Masking techniques were used to
visualize and quantify nasal and sinus aerosol deposition and retention.
Results: Using pulsating airﬂows ventilation of the paranasal sinuses was conﬁrmed
in all volunteers. 71.5±13% of the emitted aerosol deposited in the nose and
7.1±1.4% of this amount was found in the sinuses. Nasal masking with a lead
shield enabled the clear conﬁrmation of activity in the maxillary sinuses while no
sinus deposition was observed for nasal sprays. Compared to nasal sprays, nasal
retention kinetics was prolonged by about a four-fold with the VibrENT.
Conclusions: Our data provide evidence that ventilation and topical drug delivery to
the posterior nose and osteomeatal complex, including paranasal sinuses, is possible
using pulsating airﬂows. However, these ﬁndings have to be conﬁrmed in chronic
rhinosinusitis patients.
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The SideStream Plus (SS+), a breath-enhanced nebulizer, is designed to deliver an
aerosol with a high respirable fraction in a short period of time. We compared the
in vitro particle size and drug delivery characteristics of the SS+ nebulizer with
those of the LC Plus (LC+; Pari GmbH, Germany) nebulizer using colistimethate
sodium (CMS) and hypertonic saline (HS).
Particle size and drug delivery were tested using an Inspiration Elite (Philips
Respironics, NJ, USA) compressor. Five SS+ and ﬁve LC+ nebulizers were ﬁlled
with 3mL of CMS (1MIU, Promixin, Proﬁle Pharma, UK) reconstituted with 0.9%
saline and operated into a Spraytec laser diffractor for 60 s to obtain particle
size information. After washing, drying and re-ﬁlling, drug was collected onto
ﬁlters between the nebulizer and a breathing simulator (Vt = 500mL, f = 20 bpm,
I:E = 1:1.5). Nebulizers were run until 60 s after sputtering. Drug collected on the
ﬁlters was assayed using a bioassay. Each test was repeated using 4mL of HS
(Hyper Sal 7%, Pari Respiratory Equipment, VA, USA), with ﬁlters analyzed using
freezing point depression.
Colistimethate sodium
(ﬁll volume 3mL)
Hypertonic saline
(ﬁll volume 4mL)
SS+ LC+ SS+ LC+
Mass median diameter (MMD)
(standard deviation [SD])
4.43
(0.18)mm
4.45
(0.38)mm
4.18
(0.19)mm
4.84
(0.53)mm
Fine particle dose (SD) 0.172
(0.021)
MIU
0.200
(0.030)
MIU
55.4 (2.8)
mg
51.0 (6.6)
mg
Time to sputter (SD) 3min 56 s
(5 s)
5min 19 s
(27 s)
9min 17 s
(24 s)
9min 2 s
(25 s)
The in vitro particle size and drug delivery characteristics of the two nebulizers
were similar for both the drugs, which may indicate that the SS+ could be used for
the delivery of these drugs to patients with cystic ﬁbrosis.
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Objectives: Allergic bronchopulmonary aspergillosis (ABPA) is caused by an
immune mediated response including elevated IgE levels against Aspergillus. The
recommended treatment is systemic corticosteroids (CS) with potentially severe
side effects. Omalizumab binds to circulating IgE and is effective against severe
allergic astma with similar pathophysiology and therefore offers a theoretically
efﬁcient complement to CS. Omalizumab is not approved for treatment of ABPA
and not mentioned in the latest guidelines. In Sweden the ﬁrst patient with ABPA
was treated with omalizumab in 2007.
Methods: A national survey. The 4 Swedish CF-centres reported the prevalence of
ABPA and use of omalizumab and CS from January 2007 to April 2009.
Results: Nine out of 16 who were treated for ABPA were given omalizumab. Two
were not given CS because of diabetes, one also had non-tuberculous mycobacteria
(NTM). One center used only omalizumab and posaconazol in their 4 ABPA-cases.
Another center treated 3 patients with omalizumab in combination with CS and
posaconazol. Omalizumab treatment was given for 3−6 months in seven out of
9 patients. Longer treatment was given to patients who had allergic asthma. All
were given antifungal therapy. All improved. None of the omalizumab-treated has
relapsed, but observation time is short.
Conclusion: Most new ABPA-cases in Sweden are started on omalizumab as an
alternative to CS in cases with diabetes with or without NTM, but also as adjuvant
therapy to CS and in one center omalizumab is used as an alternative to CS. There
is an urgent need for studies on indications, dosing, efﬁcacy and cost-effectiveness
for this promising new therapy.
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Adherence to medication in patients with CF varies substantially. The medication
events monitoring system (MEMs) electronically records medication use.
Aim: To assess adherence levels of CF patients randomised to two treatment
regimens for azithromycin (AZM), using different indices.
Methods: Patients were prescribed AZM either 1g weekly (n = 22) or 0.5g 3 times
a week (n = 27). Data was collected over 24 weeks. Adherence measures by MEMs
were deﬁned as: Total adherence (total amount of medication taken divided by
total medication prescribed) and total number of days adhered (number of days
prescribed doses taken divided by number of days monitored). Pill counts, pharmacy
prescription pick-up and self-reports by a Morisky and a Beliefs & Behaviour
Questionnaire (BBQ) were also assessed.
Results: Study participants had a mean(SD) age of 33.4(8) years and baseline
FEV1% pred of 59.9(21.5)%. Mean(SD) measured by MEMs was 94.3(18)%
for total adherence compared to 87(15.4)% for total days adhered. Pill counts
and prescription pick-up showed approximately 100% adherence. Correlation was
observed between the Morisky and BBQ adherence measures (r2 = 0.32, p< 0.05),
but showed no correlation with MEMs data. There was positive correlation between
age and MEMs data (total adherence r2 = 0.28, p< 0.05, days adhered r2 = 0.34,
p< 0.05). Improvement in FEV1% pred of 2.8% was observed after 24 weeks
(p< 0.05).
Conclusion: Participants adhered well to initial AZM treatment with signiﬁcant
improvement in FEV1% pred. Accurate estimation of adherence to medication is
best achieved using electronic monitoring systems.
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